Search Results
Your search for Mingzhao Xing, MD, PhD ,Mingzhao Xing, MD, PhD matches 6 pages
Showing 1 - 6Epigenetic Imprinted Biomarker Test to Identify Malignant Thyroid Nodules
In a Chinese study reported in the Journal of Clinical Oncology, Xu et al found that a test for epigenetic imprinted biomarkers was highly accurate in distinguishing malignant vs benign thyroid nodules. Study Details The multicenter study involved 550 consecutively enrolled patients with nodules...
BRAF V600E and Disease-Specific Mortality in Men With Papillary Thyroid Cancer
In a large-scale retrospective analysis reported in the Journal of Clinical Oncology, Wang et al found that male sex is a predictor of poorer disease-specific survival in BRAF V600E papillary thyroid cancer. The study involved 2,638 patients (male = 623, female = 2,015) from 11 centers in 6...
Age-Associated Mortality Risk and BRAF V600E Status in Papillary Thyroid Cancer
In a study reported in the Journal of Clinical Oncology, Shen et al found evidence that BRAF V600E mutation status explains the long-recognized increased mortality risk associated with age at diagnosis in patients with papillary thyroid cancer. Study Details The study involved data from 2,638...
Cabozantinib in Medullary Thyroid Cancer: A Landscape-Shaping New Treatment
Medullary thyroid cancer is derived from parafollicular C cells in the thyroid gland. The disease is sporadic in about 75% of cases and hereditary in the remaining 25%.1 Oncogenic mutations in the gene for tyrosine kinase receptor rearranged during transfection (RET) are driver genetic alterations...
BRAF V600E Mutation Predicts Recurrence of Papillary Thyroid Cancer
In a large retrospective study reported in the Journal of Clinical Oncology, Xing et al found that presence of the BRAF V600E mutation was an independent predictor of recurrence of papillary thyroid cancer. The study involved 2,099 patients with papillary thyroid cancer consecutively selected over ...
Combined BRAF V600E and TERT Promoter Mutations Identify Aggressive and Recurrent Papillary Thyroid Cancer
In a study reported in Journal of Clinical Oncology, Xing et al found that the combined presence of BRAF V600E and TERT C228T mutations was associated with increased risk of recurrence and poor disease-free survival in patients with papillary thyroid cancer. The retrospective study included 365...
